# Intervention of pharmacist included in multidisciplinary team to reduce adverse drug event: a qualitative systematic review

Sarah Zaij, Kelly Pereira Maia, Geraldine Leguelinel-Blache, Clarisse

Roux-Marson, Jean Marie Kinowski, Hélène Richard

► To cite this version:

Sarah Zaij, Kelly Pereira Maia, Geraldine Leguelinel-Blache, Clarisse Roux-Marson, Jean Marie Kinowski, et al.. Intervention of pharmacist included in multidisciplinary team to reduce adverse drug event: a qualitative systematic review. BMC Health Services Research, 2023, 23 (1), pp.927. 10.1186/s12913-023-09512-6. doi:10.1186/s12913-023-09512-6

HAL Id: hal-05049170

https://hal.science/hal-05049170v1

Submitted on 28 Apr 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
RESEARCH

Open Access

<figure><img src="image_2.png" /></figure>

Check for
updates

# Intervention of pharmacist included in multidisciplinary team to reduce adverse drug event: a qualitative systematic review

Sarah Zaij¹*, Kelly Pereira Maia¹, Géraldine Leguelinel-Blache¹,²,³, Clarisse Roux-Marson¹,², Jean Marie Kinowski¹,² and Hélène Richard¹

**Abstract**

**Background** Preventable harm in healthcare is a growing public health challenge. In addition to the economic costs of safety failures, adverse drug events (ADE) may lead to complication or even death. Multidisciplinary care team involving a pharmacist appears to be an adequate response to prevention of adverse drug event. This qualitative systematic review aims to identify and describe multidisciplinary planned team-based care involving at least one pharmacist to limit or prevent adverse drug events in the adult patients.

**Methods** To determine the type of interprofessional collaboration to prevent adverse drug event in which a pharmacist was involved, we conducted a qualitative systematic review of the literature of randomized controlled trials. Two independent reviewers screened trials in three databases: Medline, Web of Science, ScienceDirect. Prospective studies of at least three different health professionals' interventions, one of whom was a pharmacist in the last five years were included. Two reviewers performed data extraction and quality appraisal independently. We used TIDieR checklist to appraise articles quality.

**Results** In total 803 citations were retrieved, 34 were analysed and 16 full-text articles were reviewed. Only 3 studies published an implementation evaluation. More than half of the interventions (62%) targeted elderly patients including 6 whom lived in nursing homes. Studies outcomes were heterogeneous, and we did not perform a statistical analysis of the impact of these interventions. Most teams are composed of a physician/pharmacist/nurse trio (94%; 100%; 88%). Half of the teams were composed of the primary care physician. Other professionals were included such as physical therapists (25%), social worker (19%), occupational therapists (12%), and community health educator (6%). Multidisciplinary medication review was the most common intervention and was generally structured in four steps: data collection and baseline assessment, appraisal report by health professionals, a multidisciplinary medication review meeting and a patient follow-up.

**Conclusions** The most common multidisciplinary intervention to prevent ADE in the adult population is the multidisciplinary drug review meeting at least the physician/pharmacist/nurse trio. Interventions target mostly elderly people in nursing homes, although complex chronic patients could benefit from this type of assessment.

**Trial registration** PROSPERO registration: CRD42022334685.

**Keywords** Adverse drug event, Drug-related problems, Clinical pharmacist, Multidisciplinary team

<footnote>*Correspondence:
Sarah Zaij
sarah.zaij@etu.univ-amu.fr
Full list of author information is available at the end of the article</footnote>
## Background

Adverse drug events (ADE) represent a significant but mostly preventable clinical and economic burden [1]. ADE is defined as “any undesired event involving a drug that may or may not be preventable” [2]. In the scientific literature, this concept includes several terms: adverse drug reactions (ADR), drug-related problems (DRP) and medication errors (ME).

Between 1995 and 2000 in the United States, ADE related hospitalisation were estimated at between 1.8% and 7% [3]. In Europe, a systematic review estimated shows that the frequency of ADE resulting in hospitalizations 0.5% to 12.8% [4]. In France, the two national surveys ENEIS yielded similar results: almost half of the adverse events were associated with healthcare products (48% in 2004 and 58% in 2009). In total, drugs caused 1.5 to 2.1% of stays. In 2009, half of ADE were preventable (51.2%) and 54.5% resulted in hospitalisation [5, 6].

Many studies have shown that ADE causes are multifactorial. ADE are commonly related to the patient, its diseases, medication therapy or the care system. The most common risk factors are polypharmacy and lack of medication adherence [7–13]. In United States, 53% to 58% of ADR related hospitalization were due to medication errors [14].

Clinical pharmacy is one of the strategies to improve quality of medication therapy by optimizing therapeutic choices, dispensing, and administering medications to the patient. Pharmacists, both in ambulatory care and in hospital, is one of key strategies known to prevent DRP [15–17]. Their role is to advise healthcare professionals, educate patients, review the medications to ensure the quality of medicines provided to patients [18–20].

The Global patient safety action plan 2021–2030 published by the World Health Organization promotes a safety culture. It aims to eliminate avoidable harm in health care by optimizing the working environment. Multidisciplinary and interprofessional approaches are described as the new radical approaches needed to improve patient safety [21].

Ruiz-Ramos et al. systematic review and meta-analysis published in 2021 provides evidence that cooperation of pharmacist in a multidisciplinary team improves patient safety by reducing probability of readmission and patients’ quality of life while being cost-effective [22].

So far, there is no systematic review of the literature describing the whole process such as composition, health professional interactions, tools, and types of interventions of each stakeholder.

## Aim

The purpose of this qualitative systematic review was to identify and describe the planned care provided by a multidisciplinary team involving at least one pharmacist that aim to limit or prevent ADE in the adult patients.

## Methods

### Definitions

Adverse drug event (ADE) covers several keywords in the scientific literature:

> *Adverse drug reaction (ADR) defined as "a response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease, or the modification of physiological function" [2].*

Compared to ADR, an ADE does not prejudice a causal link with an exposure, in particular to a drug [23].

> *Drug-related problems (DRP) are defined as "an event or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes" [24].*

> *Medication errors (ME) are defined by The National Coordinating Council for Medication Error Reporting and Prevention as "any error in the process of ordering or delivering a medication regardless of whether an injury occurred or the potential for injury was present" [2].*

A medication error or drug-related problem does not systematically lead to an ADE but increases the risk of occurrence. Less than 1% results in harm [2].

In the literature, the term *multidisciplinary team* is defined as “a group of professionals from two or more disciplines who work on the same project, independently or in parallel” [25].

The concept is also found as *multidisciplinary collaboration* which is a “process of problem-solving, shared responsibility for decision-making and the ability to carry out a care plan while working towards a common goal” [26, 27].

## Protocol and registration

The systematic review was conducted following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (Annexure 1). The systematic review protocol was registered with PROSPERO (International Prospective Register of Systematic Reviews) CRD42022334685 [28].
**Eligibility criteria**

**Types of studies**

A recent systematic review published in 2021 analysing the impact of pharmaceutical care in multidisciplinary teams on health outcomes included randomized clinical trials published in 2000–2018 [22]. The purpose of our article was to update data. Moreover quality of publications on health interventions are often poor [29]. Indeed, we chose to select RCT that are high-quality articles which must respect reporting guidelines.

In the last five years the number of studies on multidisciplinary intervention including a pharmacist has increased significantly. Therefore, we chose to include all clinical randomized controlled trials published in the five past years in English (2017 to March 2022). Studies were included if the interventions described at least three health professionals in which a pharmacist was involved. We have chosen not to include multidisciplinary teams providing therapeutic education to focus on care pathways aimed at preventing or limiting ADE. Systematic reviews, reviews, protocols and theoretical articles were excluded.

**Types of participants**

Only studies involving adult patients were included, whether they were hospitalized or not.

**Information sources**

We searched electronic databases including Medline, Web of Science and ScienceDirect using Medical Subject Headings and keywords related to: ADE, pharmacist intervention and multidisciplinary teams.

**Search**

**Study selection**

Two authors (SZ, HR) performed screening of identified articles independently. Articles that met the inclusion criteria were included and reviewed. A third author (KPM) reviewed the search output and resolved any disagreements between reviewers.

**Data collection process, quality, and risk of bias assessment**

Selected citations were uploaded to a Zotero database. Study data were collected and managed using REDCap electronic data capture tools [30, 31]. Data of selected studies were analyzed using TIDieR checklist (Template for Intervention Description and Replication) [29]. Each item on the assessment is worth one point.

Studies with a score of less than 9 out of 12 points have been excluded from the systematic review.

**Data items**

Data were extracted using selected articles, their protocols and implementation studies, if published. The RED-Cap form created for data collection was used to extract information from selected articles. The form had several components: study characteristics (population studied, inclusion and exclusion criteria, outcomes, relevant findings), interventions description and process (number and type of stakeholders, team coordination, communication with patients and follow-up) and finally the standardized tools used for intervention by health professionals. One form was filled out for each item selected. The results of the individual article was into an Excel spreadsheet. The results of all selected articles were summarized in three different Excel spreadsheets. These different tables are available in the results section. Missing data were specified in the tables.

**Results**

**Study selection**

A total of 803 articles were retrieved from the 3 bibliographic sources. Of this selection, 737 articles were excluded because the study was not a randomized controlled trial, a pharmacist was not involved, or only 2 health professionals were involved. After removal of the 24 duplicates and 9 protocols, 33 articles were assessed for eligibility. In the end, 16 articles were selected and included in the systematic review [32–47]. Figure 1 shows the article selection process.

**Study characteristics**

Table 1 summarizes the characteristics of the different multidisciplinary interventions included in the systematic review. Of the selected studies, 10 involved elderly patients, including 6 living in nursing homes [32, 33, 36, 37, 45, 46]. The interventions for adult patients that did not target the elderly focused on a specific chronic pathology (diabetes [42, 47], epilepsy [43], dementia [34], chronic pain treated with opioids [41] or pulmonary hypertension [38]).

**Quality appraisal**

All randomised trials scored above 9 out of 12 on the TIDieR checklist appraisal. One of the items in TIDieR included implementation studies or evaluation studies of the intervention. Selected studies adopted different methods of implementation evaluation.

In two studies, adherence to protocol were provided by a committee or reviewed by phone calls [36, 46]. Two study organised management group meeting to set
<figure><img src="image_3.png" /><figcaption>**Fig. 1** Article selection process</figcaption></figure>

objectives, monitor progress and facilitate study delivery and evaluation [36, 46]. GAPCare study use descriptive statistics to assess key parameters of fidelity [39]. One study only evaluated number of completed intervention and deviation from protocol [45]. Three research team published a process evaluation article [48–50] from three of the selected interventions [33, 36, 41].

## Results of individual studies

Outcomes of selected studies were heterogeneous. Regarding pharmaceutical criteria, six studies in the elderly or demented patients (in a nursing home or living at home) analysed inappropriate prescriptions rate using Beers criteria or STOPP/START tool (n=6; 62%) [32, 33, 36, 37, 44, 46]. Studies in adult patients <65 years assessed medication adherence [38, 43] (n=2; 12%) or treatment satisfaction [41, 47] (n=2; 12%). Roustit et al. study reported DRP or ME occurrence using NCC MERP Index for Categorizing Medication Errors tool [38] (n=1;

6%). Studies in the elderly focused on cognitive and physical capacities, falls and mortality rate [32, 33, 35, 36]. Clinical endpoints assessed in studies also included disease balance mostly focusing on one disease [38, 41, 42, 47]. Five interventions evaluated cost-effectiveness of their model through health resource use and cost (e.g. hospitalizations type and rate, consultations, medication cost) [32, 35, 38, 42, 47]. Psychosocial criteria such as depression [34, 43], anxiety [43], emotional distress [47] and patient's or caregivers' quality of life [34–36, 38, 43, 47] were assessed.

Regarding medication treatments, one study showed a significant reduction by 20% in inappropriate prescriptions, one study showed improvement of the mean Appropriate Psychotropic drug use In Dementia index sum score in the intervention group, and another study showed a positive effect of the intervention of potentially inappropriate prescribing resolution [32, 33, 46]. Toivo et al. study intention-to-treat analysis [37] did not show
<table><caption>**Table 1** Studies characteristics</caption><thead><tr><th>First author (year) (ref)</th><th>Country</th><th>Population</th><th>Sample size</th><th>Control group</th><th>Study outcomes</th><th>Results</th><th>Relevant findings</th></tr></thead><tbody><tr><td>Cateau et al. (2021) [36]</td><td>Switzerland</td><td>Aged ≥ 65 years living in nursing home</td><td>N = 62</td><td>Usual care</td><td>1. Number and dose of PIM<br>2. QoL and safety outcome (mortality, falls, use of physical restraints)</td><td>1. No significantly decrease of number but significantly PIM dose decrease<br>2. No ADE were seen on mortality, hospitalizations, falls, and restraints use, but, in the intervention group, 3 patients experienced ADE that required the reintroduction of withdrawn treatments, and a decrease in QoL is possible</td><td>Intervention showed a potential benefit in the reduction of the doses of PIM used</td></tr><tr><td>Connolly et al. (2018) [45]</td><td>New-Zealand</td><td>Aged ≥ 65 years living in nursing home</td><td>N = 247</td><td>Usual care</td><td>Emergency presentations</td><td>25% reduction in ED presentations post-intervention</td><td>Intervention, targeted at selected conditions, decreases avoidable ED admissions of high-risk residents from selected facilities</td></tr><tr><td>DeBar et al. (2022) [41]</td><td>United-State</td><td>Aged ≥ 18 years</td><td>N = 850</td><td>Usual care</td><td>1.Pain impact (PEGS score)<br>2 Disability, satisfaction, opioid and benzodiazepine use</td><td>1. Reductions in PEGS score<br>2. Reduction in pain-related disability, higher satisfaction with primary care and pain services decrease in benzodiazepine use<br>opioid use did not differ significantly</td><td>Intervention produced modest but sustained reductions in measures of pain and pain-related disability compared with usual care but did not reduce use of opioid medication</td></tr><tr><td>Desborough et al. (2020) [32]</td><td>United Kingdom</td><td>Aged ≥ 65 years living in nursing and residential home</td><td>N = 826</td><td>Usual care</td><td>1. Number of falls and PIM<br>2. Hospital admissions, deaths, economic evaluation</td><td>1. No significant differences for falls outcome, 20% decrease pims at 12 months<br>2. No significant difference ED admissions or deaths. Estimated cost was higher in the intervention group</td><td>Intervention improved medication appropriateness but failed to demonstrate improvements in clinical outcomes</td></tr></tbody></table>
<table><caption>**Table 1 (continued)**</caption><thead><tr><th>First author (year) (ref)</th><th>Country</th><th>Population</th><th>Sample size</th><th>Control group</th><th>Study outcomes</th><th>Results</th><th>Relevant findings</th></tr></thead><tbody><tr><td>Goldberg et al. (2020) [39]</td><td>United-State</td><td>Aged ≥ 65 years</td><td>N = 110</td><td>Usual care</td><td>Assess the feasibility and acceptability of the GAPCare (Geriatric Acute and Post-Acute Fall Prevention) intervention in the ED</td><td>98.2% received the pharmacy consult, 83.6% physical therapist consult, ED length of stay was not increased in the intervention arm, Pharmacy consult recommended by 100% of participants and 97.6% of clinicians. Physical therapist consult recommended by 95% of participants and 95.8% of clinicians</td><td>These findings support the feasibility and acceptability of the intervention in the ED</td></tr><tr><td>Kari et al. (2021) [35]</td><td>Finland</td><td>Aged ≥ 75 years</td><td>N = 277</td><td>Usual care</td><td>1. QoL<br>2. Physical performance, health resource use and cost, incremental cost effectiveness ratio</td><td>1. No difference in QoL<br>2. Physical performance: Unclear effect<br>incremental cost effectiveness ratio ~73 638 €/QALY</td><td>The cost-utility analysis showed that the intervention dominated usual care. However, it had no effect on QoL and the effect towards physical performance remained unclear</td></tr><tr><td>Levine et al. (2021) [44]</td><td>United-State</td><td>Aged ≥ 65 years living at home</td><td>N = 105</td><td>Usual care</td><td>Retrospective analysis of medication therapy problems related to cognition<br>Classification:<br>• Indication: underuse or overuse;<br>• Effectiveness: ineffective agent or low dose;<br>• Safety: ADE, unsafe medication (e.g., PIM), drug interaction, or high dose</td><td>Medication therapy problem(MTP) description:<br>• 34% concern indication (79% underuse, 21% overuse)<br>• 13% concern effectiveness<br>• 52% concern safety: benzodiazepines and anticholinergics frequently implicated<br>Recommendations:<br>• 23% discontinuation<br>• 19% dose reduction<br>MTP involving cognition: among 79% patients</td><td>Intervention is effective to identify cognitively harmful medications, dementia treatment side effects, and untreated cognitive conditions</td></tr><tr><td>Li et al. (2021) [40]</td><td>United-State</td><td>Aged ≥ 65 years</td><td>N = 605</td><td>Usual care</td><td>1. ADE incidence<br>2. Hospitalizations (ED), chemotherapy dose</td><td>1. Significant 10.1% reduction incidence of grade 3 or higher chemotherapy-related toxic effects<br>2. No significant differences</td><td>Intervention significantly reduced grade 3 or higher chemotherapy-related toxic effects in older adults with cancer</td></tr></tbody></table>
<table><caption>**Table 1 (continued)**</caption><thead><tr><th>First author (year) (ref)</th><th>Country</th><th>Population</th><th>Sample size</th><th>Control group</th><th>Study outcomes</th><th>Results</th><th>Relevant findings</th></tr></thead><tbody><tr><td>Lu et al. (2021) [42]</td><td>China</td><td>18 years &lt; aged &lt; 75 years</td><td>N = 120</td><td>Usual care</td><td>1. Hb1Ac &lt; 7% from baseline to 6 months<br>2. Changes in fasting blood glucose, daily medication cost, number of drug types taken daily and hypoglycemic events</td><td>1. Hb1Ac improved<br>2. No statistically significant decrease fasting blood glucose, costs. Significant decrease in number of medication types and hypoglycemic events</td><td>Intervention improved the rate of Hb1Ac for patients with type 2 diabetes mellitus</td></tr><tr><td>Possin et al. (2019) [34]</td><td>United-State</td><td>Aged &gt; 45 years with dementia</td><td>N = 780</td><td>Usual care</td><td>1. Quality of life in Alzheimer's disease<br>2. Hospitalization (ED) and use health services</td><td>1. Significant improvement of QoL<br>2. Decrease of ED visits, of caregiver depression and caregiver burden</td><td>Intervention mitigates the growing societal and economic burdens of dementia</td></tr><tr><td>Roustit et al. (2020) [38]</td><td>France</td><td>Patients with any type of pulmonary hypertension</td><td>N = 92</td><td>Usual care</td><td>1. Number of DRP (including ADE and ME)<br>2. Clinical worsening, adherence, quality of life and satisfaction with medications</td><td>1. No significant difference<br>2. No significant difference in time to clinical worsening, therapeutic adherence, satisfaction or QoL<br>Collaborative care decreased costs of drug-related hospitalizations</td><td>Intervention improved the outcome of drug-related problems and reduced the costs of related hospitalization. However, we observed no efficacy on medication errors, clinical outcomes, or medication adherence</td></tr><tr><td>Siaw et al. (2018) [47]</td><td>Singapore</td><td>Aged ≥ 18 years</td><td>N = 411</td><td>Usual care</td><td>1. Hb1Ac, systolic blood pressure, low density lipoprotein and triglyceride<br>2. Evaluation emotional distress and treatment satisfaction, health service utilization rates and costs</td><td>1. Hb1Ac improvement of 0.8%<br>2. Improvements in PAID and DTSQ score, reduction in physician workload and average cost savings of $91,01 per patient</td><td>The positive clinical, humanistic, economic outcomes highlighted the value of multidisciplinary collaborative care for Asian diabetic patients, thereby supporting the effectiveness of this approach in managing chronic diseases</td></tr><tr><td>Strauven et al. (2019) [33]</td><td>Belgium</td><td>Aged ≥ 65 years living in nursing home</td><td>N = 1804</td><td>Usual care</td><td>1. PIM (success = at least 1 PIM solved)<br>2. Mortality and healthcare use and DRP</td><td>1. Significant effect in favor of the intervention<br>2. No significant difference between groups for most clinical outcomes</td><td>Intervention tested has successfully improved appropriateness of prescribing in nursing homes</td></tr><tr><td>Toivo et al. (2019) [37]</td><td>Finland</td><td>Aged ≥ 65 years living in nursing home</td><td>N = 129</td><td>Usual care</td><td>PIM</td><td>Intention-to-treat analysis shows no impact on the medication risks but the per protocol analysis shows tendency for effectiveness particularly in optimizing central nervous system medication use</td><td>Intervention indicated tendency for effectiveness when implemented as planned</td></tr></tbody></table>
<table><caption>**Table 1 (continued)**</caption><thead><tr><th>First author (year) (ref)</th><th>Country</th><th>Population</th><th>Sample size</th><th>Control group</th><th>Study outcomes</th><th>Results</th><th>Relevant findings</th></tr></thead><tbody><tr><td>Van Der Spek et al. (2018) [46]</td><td>Netherlands</td><td>Aged ≥ 65 years living in nursing home</td><td>N = 380</td><td>Usual care</td><td>Appropriateness of psychotropic drug prescription (APID score)</td><td>Significant improvement APID index sum score</td><td>The implementation of the intervention is effective</td></tr><tr><td>Zheng et al. (2019) [43]</td><td>China</td><td>Aged ≥ 18 years</td><td>N = 194</td><td>Usual care</td><td>Evaluation of depression, anxiety, medication adherence, QoL, number of seizures</td><td>Significantly reduced of patients with severe depression and anxiety Increased of patients with moderate-to-high adherence Increase QoL (QOLIE-31 score) Both groups: significant increase in patients with a low seizure frequency after 12-month</td><td>Intervention improved psychiatric comorbidities, medication adherence, and QoL</td></tr></tbody></table>

ADE adverse drug event, APID score Appropriateness of psychotropic drug prescription, DRP drug related problem, ED emergency department, PEGS Pain, Enjoyment, General Activity scale, PIM potentially inappropriate medication, QoL quality of life, QALY Quality-adjusted life year, ME medication error, MTP medication therapy problem
an impact on the use of inappropriate medications (psychotropic, anticholinergic, and serotonergic), but the per-protocol analysis indicated a trend toward effectiveness. One study did not show a significant reduction in the number of chronic potentially inappropriate medication (PIMs) but was able to show a reduction in their dose after intervention by 28% [36]. GAIN intervention showed a 20% reduction in the incidence of grade 3 or greater chemotherapy-related toxicities [40]. Of the two studies that assessed patient medication adherence, Zheng et al. study showed improvement (moderate to high) to antiepileptic medication adherence [38, 43].

Two studies in diabetic patients, IMPACT intervention and Lu et al. study showed significant improvement in glycated hemoglobin measurement [42, 47]. Three studies that compared mortality rates between the two groups did not show significant improvement after intervention [32, 33, 36]. Two studies showed no impact of the intervention on the number of falls in the included elderly [32, 36]. Regarding hospitalizations, Connolly et al. study proved a 25% reduction in emergency presentation over 9 months after the intervention [45] and Possin et al. showed a significant reduction in emergency visits. Strauven et al., the median length of hospital stay was significantly longer in the control group. Two studies showed no impact on the number of hospitalizations after intervention [32, 40]. In terms of patient care pathways, two studies showed a significant reduction in emergency department presentations [45] and emergency department visits [34]. Roustit et al. did not show significant difference on clinical outcomes but demonstrated a cost decreased of drug-related hospitalizations [38]. In Kari et al., the incremental cost effectiveness ratio was valued at – 73 638€/ QALY [35].

Intervention decreased significantly caregiver depression and burden [34], reduced the number of patients with severe depression and anxiety [43] and improved patients evaluation of diabetes-related emotional distress [47]. Regarding patients' or caregivers' quality of life evaluation, two studies showed a significant improvement [34, 43].

Table 2 lists for each stage of the interventions, stakeholders, their missions, details of team coordination, communication with the patient modalities and patient's follow-up. Intervention steps are sorted in chronological order. Information may be incomplete due to a lack of interventions description in articles.

Half of the intervention teams consisted of a tripartite team including a physician, a nurse and a pharmacist [32, 33, 35–38, 42, 46] (n=8; 50%).

Physician are included in 15 of selected studies (94%). In one study, participants were referred by treating providers but the primary care physician did not provide

care intervention [34]. In 50% of the studies, the team is composed of the primary care physician. Five studies involved specialist doctors: geriatricians [44, 45] (n=2; 12%), psychiatrists [43, 44] (n=2; 12%), emergency department clinicians [39] (n=1; 6%), epileptologists [43] (n=1; 6%). Generally, physicians were involved in the decision making of care plans during multidisciplinary meetings during which they retain possibility of refusing proposed modifications. In five studies patient received a clinical assessment from the physician [39, 40, 42, 43, 47].

Among the 16 studies, the level of training of the pharmacists was different. Four studies involved a clinical pharmacist [32, 38, 44, 45] (n=4; 25%), three studies involved a community pharmacist [33, 35, 37] (n=3; 19%), two studies had a hospital pharmacist as part of the team [39, 42] (n=2; 12%) and seven studies did not specify the pharmacist's specialization [34, 40–42, 46] (n=7; 44%). Three studies involved a "clinically trained" pharmacists [34, 36, 37] (n=3; 19%). Medication reconciliation was performed by a pharmacist technician in one [32] and by a pharmacist in two studies [35, 39]. Pharmacists performed a medication assessment to identify, address and help to resolve potential DRP [44], proposed potential therapeutic alternatives, or adjustment medication [41]. They use standardised tools such as STOPP/START tool to review medication in the elderly patients [32, 33, 36, 46]. When seen in consultation with the patient (by telephone, home visit or face-to-face), they identified patient's needs, knowledge, skills and provided motivation and education interview [35, 38, 39, 42, 43, 47]. They also helped them with new treatment plans [42], conceived pharmaceutical plan [32, 39, 40, 42, 45], provided prescription [47], and assessed medication adherence [36, 38].

Nurses were included in 14 of the 16 selected studies (88%). One study included "care home staff" without specifying its composition [32] and one study did not include a nurse [39]. Advanced practice nurse [34, 44] or specialist nurse (gerontology [45], epilepsy [43], diabetes educator [47]) took action in five studies (n=5; 31%). They performed clinical assessment [35, 37, 40, 41, 44, 45, 47], medication reconciliation [37, 44], DRP risk assessment [37], patient education and care coordination [40, 41, 43, 47]. For example, in Levine's study, advanced practice nurse performed an in-home battery of clinical assessments designed to gain deeper clinical understanding of dementia, depression, and delirium-related symptoms, as well as to guide clinical triggers for referral to other members of the team [44].

Other health professionals were involved: social workers [34, 40, 44] (n=3; 19%), community health educator [44] (n=1; 6%), physical therapists [39–41, 44] (n=4; 25%), and occupational therapists [40, 44] (n=2; 12%).
<table><caption>**Table 2** Interventions description and process</caption><thead><tr><th>First author (year) (ref)</th><th>Stages of the intervention</th><th>Stakeholder</th><th>Team coordination</th><th>Communication with patient</th><th>Patient follow-up</th></tr></thead><tbody><tr><td>Cateau et al. (2021) [36]</td><td>1. Deprescribing-focused medication review and adherence assessment, Quality of life evaluation<br>2. Creation of a treatment modification plan for each participant</td><td>Pharmacist<br>Physician<br>Pharmacist<br>Nurse</td><td>Electronic and paper form<br>Clinical staff (paper form)</td><td>First visit in nursing home<br>Validation of the plan with the participant or her/his representative</td><td>Second visit 4 months after first one</td></tr><tr><td>Connolly et al. (2018) [45]</td><td>1. Baseline assessment (identifying needs and facility care plan)<br>2. Clinical coaching for nurses and caregivers<br>3. Multidisciplinary meetings: medication and care plan review</td><td>Gerontology nurse specialist<br>facility senior nurse<br>For nurses and caregivers<br>Study geriatrician<br>Gerontology nurse Specialist<br>Pharmacist<br>General practitioner<br>Senior nurse(s)</td><td>3 one-hour meetings<br>(1 per month, 6 residents considered per meeting)</td><td>No information</td><td>9 months before and 9 months after intervention</td></tr><tr><td>DeBar et al. (2022) [41]</td><td>1. Comprehensive intake evaluation of pain (causes of pain exacerbation, impact functioning, depression, anxiety)<br>2. Medication review (potential alternatives to opioids or other adjustments of psychotropic medications)<br>3. Set physical activity goals, identify adaptations to be put in place for the adapted movement intervention)<br>4. Cognitive behavioral therapy-based pain coping skills training and adapted movement practice<br>5. PCP consultation and patient outreach</td><td>Nurse case manager<br>or behavioral specialist<br>Pharmacist<br>Physical therapist<br>Nurse case manager<br>behavioral specialist<br>Primary care physician</td><td>Biweekly telephone consultation with clinical investigators on the study</td><td>Face-to-face 2 sessions<br>No information</td><td>12 weeks<br>Individual phone coaching<br>Face-to-face 1 session<br>12 weekly group sessions<br>with patients<br>Additional phone calls</td></tr></tbody></table>
<table><caption>**Table 2 (continued)**</caption><thead><tr><th>First author (year) (ref)</th><th>Stages of the intervention</th><th>Stakeholder</th><th>Team coordination</th><th>Communication with patient</th><th>Patient follow-up</th></tr></thead><tbody><tr><td rowspan="3">Desborough et al. (2020) [32]</td><td>1. Medication review preparation (data extraction)</td><td>Pharmacist technician</td><td rowspan="3">Face-to-face 2 h meeting (15 residents considered per meeting) repeated after 6 months; Written details communicated to care home staff and community pharmacist</td><td rowspan="3">No information</td><td rowspan="3">12 months</td></tr><tr><td>2. Preparation pharmaceutical care plan</td><td>Clinical pharmacist</td></tr><tr><td>3. Multidisciplinary medication review</td><td>General practitioner<br>Clinical pharmacist<br>Pharmacist technician<br>Care homes staff</td></tr><tr><td rowspan="3">Goldberg et al. (2020) [39]</td><td>1. Clinical assessment</td><td>ED clinician</td><td rowspan="3">Written report to participant, ED team, and faxed to PCP</td><td rowspan="3">Face-to-face<br>20 min face-to-face consultation</td><td rowspan="3">No follow-up</td></tr><tr><td>2. Medication therapy management session; reconciliation, motivational interview, medication-related plan</td><td>Pharmacist</td></tr><tr><td>3. Fall risk assessment and plan</td><td>Physical therapist</td></tr><tr><td rowspan="4">Kari et al. (2021) [35]</td><td>1. Self-care evaluation</td><td>Patient</td><td rowspan="4">Action plan in writing and in person to each participant and ED treatment team and faxed to PCP<br>Self-questionnaire</td><td rowspan="4">20 min face-to-face consultation</td><td rowspan="4">2 years</td></tr><tr><td>2. Clinical medication review: reconciliation, medication review, recommendations</td><td>Pharmacist</td></tr><tr><td>3. Health review</td><td>Nurse</td></tr><tr><td>4. Interprofessional team meeting; discussion about DRP and health related issues, creation care plan</td><td>Physician<br>Pharmacist<br>Nurse</td></tr></tbody></table>
<table><caption>**Table 2 (continued)**</caption><thead><tr><th>First author (year) (ref)</th><th>Stages of the intervention</th><th>Stakeholder</th><th>Team coordination</th><th>Communication with patient</th><th>Patient follow-up</th></tr></thead><tbody><tr><td>Levine et al. (2021) [44]</td><td>1. Comprehensive clinical assessments and medication reconciliation (focused on cognitive impairment and depression)<br>2. Medication assessment: identifying addressing, and helping resolve potential DRP<br>3. Conference to establish the comprehensive medication review: decision of recommendations to be forwarded to usual care providers via faxed letter<br>3. Problem Solving Therapy (PST) to patients with significant depressive symptoms<br>4. Modified protocol-driven Care for Persons with Dementia in their Environments (COPE) intervention<br>5. Protocol-driven Otago Exercise program<br>6. Nutrition assessment<br>7. Addressing social determinants of health</td><td>Advanced practice nurse<br>Clinical pharmacist<br>Geriatrician<br>Psychiatrist<br>advanced practice nurse<br>Licensed clinical social worker<br>Occupational therapist<br>Physical therapist<br>Dietician<br>Community Health Educator</td><td>Weekly electronic communication, in-person meetings three times annually<br>No direct contact with the patient<br>6 weekly sessions face-to-face or by telephone<br>4 to 10 in-home visits<br>4 in-home visits and 2 phone calls<br>In-home and telephone contact<br>Letters and phone contact</td><td>4 home visits (2 h the 1st and 1 h following) and 8 telephone contacts<br>No direct contact with the patient<br>6 weekly sessions face-to-face or by telephone<br>4 to 10 in-home visits<br>4 in-home visits and 2 phone calls<br>In-home and telephone contact<br>Letters and phone contact</td><td>12 months monthly call by the advanced practice nurse</td></tr></tbody></table>
<table><caption>**Table 2 (continued)**</caption><thead><tr><th>First author (year) (ref)</th><th>Stages of the intervention</th><th>Stakeholder</th><th>Team coordination</th><th>Communication with patient</th><th>Patient follow-up</th></tr></thead><tbody><tr><td>Li et al. (2021) [40]</td><td>1. Geriatric assessment: evaluation physical function, comorbidity, nutritional status, polypharmacy, social support, cognition, and psychological status</td><td>Physician research team</td><td>No information</td><td>No information</td><td>Until chemotherapy completion or 6 months after initiation, whichever occurred first</td></tr><tr><td></td><td>2. Multidisciplinary geriatric assessment review: intervention plan and appropriate referrals</td><td>Oncologist nurse practitioner social worker physical/occupation therapist nutritionist pharmacist</td><td>No information</td><td>No information</td><td></td></tr><tr><td></td><td>3. Additional support (patient education, care coordination, additional specialty referrals)</td><td>Nurse practitioner</td><td>No information</td><td>No information</td><td></td></tr><tr><td>Lu et al. (2021) [42]</td><td>1. In-hospital pharmacy consultation, medication evaluation, and treatment</td><td>Physician Pharmacist Nurse</td><td></td><td>Face-to-face pharmacy consultations for each patient</td><td>1 week after discharge, once a week 1st month, every 2 weeks 2-3 and once a month until 6th month</td></tr><tr><td></td><td>2. Out-of-hospital medication consultation, guidance, and adjustment of new treatment plans</td><td>Pharmacist physician</td><td>Web-based social media platform (WeChat)</td><td>Web-based social media platform (WeChat)</td><td></td></tr><tr><td>Possin et al. (2019) [34]</td><td>1. Screening for problems, providing personalized support and standardized education</td><td>Care team navigator</td><td>Contact prescribing providers via secure facsimile</td><td>Phone calls</td><td>Monthly phone calls by the care team navigator and survey at baseline, 6 and 12 months</td></tr><tr><td></td><td>2. Weekly case review and supervision</td><td>Care team navigator Advanced practice nurse social worker</td><td>Direct consultation with care team navigator</td><td>Direct consultation with patient and caregivers</td><td></td></tr><tr><td></td><td>3. Medication review at enrollment (recommendations send by the care team navigator to providers and caregivers)</td><td>Pharmacist</td><td>Discussion with advanced practice nurse</td><td>Consultation via telephone and secure messaging</td><td></td></tr><tr><td>Roustit et al. (2020) [38]</td><td>1. Patient interview: medication review, identifying patient's needs, knowledge and skills, providing education</td><td>Pharmacist</td><td>Standardized report form</td><td>Face-to-face session at least once every 6 months</td><td>At baseline, 3, 6, 12 and 18 months</td></tr><tr><td></td><td>2. Discussion of pharmacist's recommendations</td><td>Physician Pharmacist Nurse</td><td>Collaborative discussion</td><td></td><td></td></tr></tbody></table>
<table><caption>**Table 2 (continued)**</caption><thead><tr><th>First author (year) (ref)</th><th>Stages of the intervention</th><th>Stakeholder</th><th>Team coordination</th><th>Communication with patient</th><th>Patient follow-up</th></tr></thead><tbody><tr><td>Siaj et al. (2018) [47]</td><td>1. Patient diagnosis, assessment of diabetes severity, prescribing medications<br>2. Managing CAREPILLS<sup>a</sup>, optimizing medication using SIGN<sup>b</sup> algorithm, furnishing prescription<br>3. Self-care counselling and basic foot and eye screenings<br>4. Dietary counselling includes: carbohydrate counting, healthy food choices, weight management</td><td>Physician<br>Clinical pharmacist<br>Diabetes nurse educator<br>Dietician</td><td>No information</td><td>No information<br>Face-to-face session 20-30 min<br>Face-to-face session 20-30 min<br>Face-to-face session 20-30 min</td><td>Every 4 to 6 weeks for 6 months: face-to-face visits or phone calls by the clinical pharmacist</td></tr><tr><td>Strauven et al. (2019) [33]</td><td>1. Blended training program (e-learning and workshops)<br>2. Local interdisciplinary meetings (discussion of the use of antidepressants and lipid-lowering drugs)<br>3. Interdisciplinary case conferences (medication review with web application)<br>1. Risk assessment: medication reconciliation, DRP risk assessment, clinical tests<br>2. Prescription review<br>3. Triage meetings: decision on actions for patients with clinically significant DRP<br>4. If a comprehensive medication review decided during triage meeting<br>5. Case-conferences: collaborative medication review</td><td>General practitioner (GP)<br>Pharmacist<br>nurse<br>Practical nurse<br>Community pharmacist<br>Coordinating pharmacist<br>leading home care physician<br>home care nurse<br>Community pharmacist<br>Coordinating pharmacist<br>Community pharmacist<br>physician</td><td>Face-to-face workshops<br>2 two-hours face-to-face meetings (baseline and month 3 or 4)<br>20 min face-to-face meeting every 4 months<br>Written report to physicians delivered by the nurse<br>2 h face-to-face meeting<br>No information<br>Face-to-face meeting</td><td>No resident participation patient and family received feedback from the nurse or GP<br>15 months<br>Home visit<br>Clinical patient interview and 3 months contacting practical nurses and/or patient</td><td>Baseline, 12 and 24 months</td></tr><tr><td>Toivo et al. (2019) [37]</td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table>
<table><caption>**Table 2 (continued)**</caption><thead><tr><th>First author (year) (ref)</th><th>Stages of the intervention</th><th>Stakeholder</th><th>Team coordination</th><th>Communication with patient</th><th>Patient follow-up</th></tr></thead><tbody><tr><td>Van Der Spek et al. (2018) [46]</td><td>1. Education to medication review preparation<br>2. Conduct of multidisciplinary medication review at 0-, 6- and 12 months (focus psycho-tropic drugs use and neuropsychiatric symptoms)<br>3. Evaluation meetings on the process at 6 and 12 months</td><td>Physician<br>Pharmacist<br>Nurse</td><td>Face-to-face meeting</td><td>Participants were not directly involved in the study</td><td>Baseline, 6, 12 and 18 months</td></tr><tr><td>Zheng et al. (2019) [43]</td><td>1. Interview in epilepsy clinic (evaluation of epilepsy knowledge and self-management skills, and depression)<br>± score of BDI ≥ 16 or the score of BAI ≥ 37<br>± score of MMAS8 &lt; 6<br>2. Online consultation: educational information<br>3. Multidisciplinary education group</td><td>Epileptologist<br>± psychiatrist<br>± pharmacist</td><td>No information</td><td>Face-to-face</td><td>4 weeks, 3 months intervals (for 12 months)</td></tr><tr><td></td><td></td><td>Epilepsy specialist nurse</td><td></td><td>Web-based social media platform (WeChat)</td><td></td></tr><tr><td></td><td></td><td>Epileptologist<br>Psychiatrist<br>epilepsy specialist nurse<br>pharmacist<br>Patient</td><td></td><td>Twice a year meeting in presence of patients</td><td></td></tr></tbody></table>

<footnote>a CAREPILLS: Closer monitoring, Adherence problem, Resistance to drug therapy, Empowerment in patient's own therapy, Polypharmacy, Insulin titration, Lack in drug knowledge, Lack in drug administration techniques and Switching of drugs</footnote>

<footnote>b SIGN: Symptom-based Insulin adjustment for Glucose Normalization); PCP: primary care physician; ED: emergency department</footnote>
In the Care Ecosystem intervention, community health worker connected the different health care professionals with each other and with the patient under nurse supervision [34]. In Possin et al. study, community health educator was a pivotal person who provided a link between the patient or caregiver and specialized health professionals [34].

Interventions typically involved several steps (Fig. 2). The first is to collect clinical, biological, pharmaceutical, or social data relevant to the analysis. Most of the time, this research was done by the nurse, pharmacist, or a community health educator. Assessment questionnaires were filled in either by the health professional or by the patient himself. For example, in GAIN intervention, patient and health professionals complete an in-depth geriatric assessment. Patient portion included self-reported measures of (psychological state, social activity/ support) and health care professional portion consisted of clinical assessment such as Karnofsky and Fulmer SPICES assessment [40].

Following data collection, the health professionals in their field of expertise prepare a detailed analysis report. Their analysis used standardized tools, the list of which is detailed (Table 3). These expert reports were either in the form of paper reports [32, 35–39] or electronic reports [36]. The purpose of this step was to develop a baseline assessment, to screen for problems, to identify the patient’s needs, drug-related risks and to propose solutions.

The third step was a multidisciplinary meeting bringing together all health professionals included. Ten studies performed a multidisciplinary medication review (n = 10; 62%) [32–37, 40, 44–46]. Together, health professionals reviewed patients’ medication plan considering their previous evaluation. Medication review helped them to

identify inappropriate medications, reduce the number of medication errors, and increase frequency of monitoring. Multidisciplinary team decided on a care plan, a personalized medication plan and recommended a consultation with a health professional if necessary. For example, if pain was identified a supportive care/pain management referral was proposed [40]. In Levine’s study, problem-solving therapy by a social worker in consultation or by teleconsultation was offered if significant depressive symptoms were detected during the clinical assessment at home by an advanced practice nurse [44]. After multidisciplinary meetings a feedback was given by the general practitioner or nurse in two studies to the patients or caregivers [33, 35].

Communication between health professionals took place mainly during interprofessional meetings. Meetings were held face-to-face, and duration and frequency were not always mentioned. The intervention lasted one hour [45] to two hours [32, 33, 37]. These meetings were weekly [45], quarterly [44], four-monthly [33], six-monthly [32] or annually [43]. Three studies did not report multidisciplinary meetings [39, 47, 48]. In GAP-Care study, healthcare professionals shared information with each other in writing [39]. When the primary care team was not included in the multidisciplinary meeting, a report was sent to them [32, 37, 39]. In Lu et al. study, care team used WeChat app to treat and monitor patient’s medications [42].

Communication with patient took place mainly through consultations in 11 studies. Of these, six were performed by the nurse [34, 35, 37, 41, 47, 48], seven by the pharmacist [35, 36, 38, 39, 42, 43, 47]. In Levine’s study, pharmacist had no direct contact with the patient. In two studies, patients were contacted by the pharmacist by phone or via an app [34, 42]. Patients

<figure><img src="image_4.png" /><figcaption>**Fig. 2** Interventions process</figcaption></figure>
<table><caption>**Table 3** Standardized tools used in selected interventions</caption><thead><tr><td>Evaluation</td><td>Tool used</td><td>Study</td></tr></thead><tbody><tr><td rowspan="5">Pharmaceutical analysis</td><td>Systematic Tool to Reduce Inappropriate Prescribing (STRIP)</td><td>Van Der Spek et al. (2018) [46]</td></tr><tr><td>STOPP/START tool</td><td>Desborough et al. (2020) [32]; Strauven et al. (2019) [33]; Cateau et al. (2021) [36]; Van Der Spek et al. (2018) [46]</td></tr><tr><td>SFINX (electronic drug-drug interaction screening data base)</td><td>Toivo et al. (2019) [37]; Kari et al. (2021) [35]</td></tr><tr><td>Appropriate Psychotropic drug use in dementia index</td><td>Van Der Spek et al. (2018) [46]</td></tr><tr><td>Medication appropriateness Index (MAI)</td><td>Van Der Spek et al. (2018) [46]</td></tr><tr><td rowspan="2">Medication adherence</td><td>Beers criteria (2015)</td><td>Levine et al. (2021) [44]; Strauven et al. (2019) [33]; Toivo et al. (2019) [37]; Goldberg et al. (2020) [39]</td></tr><tr><td>Morisky Medication Adherence Scale -8</td><td>Zheng et al. (2019) [43]; Kari et al. (2021) [35]; Roustit et al. (2020) [38]</td></tr><tr><td rowspan="2">Treatment satisfaction</td><td>Diabete Treatment Satisfaction Questionnaire (DTSQ)</td><td>Siaw et al. (2018) [47]</td></tr><tr><td>Treatment Satisfaction with Medicines Questionnaires (SATMED-Q)</td><td>Roustit et al. (2020) [38]</td></tr><tr><td rowspan="2">DRP assessment risk</td><td>Drug Related Problem Risk Assessment TOOL (DRP-RAT)</td><td>Toivo et al. (2019) [37]</td></tr><tr><td>Cancer and Aging Research Group (CARG) chemotherapy toxicity risk score,</td><td>Li et al. (2021) [40]</td></tr><tr><td rowspan="5">DRP classification</td><td>Basger et al. DRP classification</td><td>Strauven et al. (2019) [33]</td></tr><tr><td>NCC MERP Index for Categorizing Medication Errors</td><td>Roustit et al. (2020) [38]</td></tr><tr><td>PCNE DRP classification V6.2</td><td>Strauven et al. (2019) [33]</td></tr><tr><td>SFPC Pharmacist Intervention classification</td><td>Roustit et al. (2020) [38]</td></tr><tr><td>Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0)</td><td>Li et al. (2021) [40]</td></tr><tr><td rowspan="3">DRP assessment of severity</td><td>Common Terminology Criteria for Adverse Events (CTCAE) v 5.0</td><td>Cateau et al. (2021) [36]</td></tr><tr><td>IHI Global Trigger Tool for measuring Adverse Events</td><td>Roustit et al. (2020) [38]</td></tr><tr><td>UKU Udvvalg fo kliniske undersogleser side effect rating scale</td><td>Van Der Spek et al. (2018) [46]</td></tr><tr><td>DRP assessment of causality</td><td>CH E2A guidelines</td><td>Cateau et al. (2021) [36]</td></tr><tr><td rowspan="7">Quality of life</td><td>EQ 5D 5L</td><td>Cateau et al. (2021) [36]; DeBar et al. (2022) [41]</td></tr><tr><td>QUALIDEM</td><td>Van Der Spek et al. (2018) [46]</td></tr><tr><td>Short Form 36 Health Survey</td><td>Kari et al. (2021) [35]; Roustit et al. (2020) [38]</td></tr><tr><td>Quality of life in Epilepsy 31</td><td>Zheng et al. (2019) [43]</td></tr><tr><td>Quality of Life Alzheimer's Disease Scale</td><td>Levine et al. (2021) [44]; Possin et al. (2019) [34]</td></tr><tr><td>Patient Health Questionnaire PHQ9 depression measure</td><td>Levine et al. (2021) [44]; Possin et al. (2019) [34]</td></tr><tr><td>Beck Depression Inventory</td><td>Zheng et al. (2019) [43]</td></tr><tr><td rowspan="10">Depression, anxiety, emotional burden and sleep quality</td><td>Beck Anxiety Inventory</td><td>Zheng et al. (2019) [43]</td></tr><tr><td>GRID Hamilton Rating Scale (GRID-HAMD)</td><td>Levine et al. (2021) [44]</td></tr><tr><td>Center for Epidemiologic Studies—Depression scale</td><td>Levine et al. (2021) [44]</td></tr><tr><td>Geriatric Depression Scale-15 (GDS 15)</td><td>Possin et al. (2019) [34]; Toivo et al. (2019) [37]</td></tr><tr><td>Nijmegen Observer-Rated Depression scale (NORD)</td><td>Van Der Spek et al. (2018) [46]</td></tr><tr><td>Minimum Data Set Depression Rating Scale (MDS-DRS)</td><td>Van Der Spek et al. (2018) [46]</td></tr><tr><td>Zarit Burden Interview</td><td>Possin et al. (2019) [34]</td></tr><tr><td>Caregiver Strain Index</td><td>Possin et al. (2019) [34]</td></tr><tr><td>Problem Areas in Diabetes Questionnaire (PAID)</td><td>Siaw et al. (2018) [47]</td></tr><tr><td>Pittsburgh Sleep Quality Index</td><td>Levine et al. (2021) [44]; Possin et al. (2019) [34]</td></tr><tr><td>Literacy assessment</td><td>Rapid Assessment of Adult Literacy</td><td>Possin et al. (2019) [34]</td></tr></tbody></table>
<table><caption>**Table 3** (continued)</caption><thead><tr><td>Evaluation</td><td>Tool used</td><td>Study</td></tr></thead><tbody><tr><td rowspan="3">Social assessment</td><td>Medical Outcomes Study Social Support Survey Instrument</td><td>Li et al. (2021) [40]</td></tr><tr><td>Medical Outcomes Study Social Activity Limitation Measure</td><td>Li et al. (2021) [40]</td></tr><tr><td>Seeman and Berkman Social Ties</td><td>Li et al. (2021) [40]</td></tr><tr><td rowspan="5">Daily activities Disability</td><td>Revised Index of Social Engagement (RISE)</td><td>Van Der Spek et al. (2018) [46]</td></tr><tr><td>WHO Disability Assessment Schedule</td><td>Levine et al. (2021) [44]</td></tr><tr><td>Instrumental Activities of Daily Living (IADL)</td><td>Li et al. (2021) [40]</td></tr><tr><td>Barthel Index for Activities of Daily Living (ADL)</td><td>Goldberg et al. (2020) [39]</td></tr><tr><td>Minimum Data Set Resident Assessment Instrument (MDS-RAI)</td><td>Van Der Spek et al. (2018) [46]</td></tr><tr><td rowspan="2">Pain assessment</td><td>Roland Morris Questionnaire</td><td>DeBar et al. (2022) [41]</td></tr><tr><td>PEG-3 Item Pain Scale</td><td>DeBar et al. (2022) [41]</td></tr><tr><td rowspan="7">Clinical tools</td><td>Pain assessment in Advance Dementia Tool</td><td>Possin et al. (2019) [34]</td></tr><tr><td>Incontinence Impact Questionnaire</td><td>Levine et al. (2021) [44]</td></tr><tr><td>Urogenital Distress Inventory</td><td>Levine et al. (2021) [44]</td></tr><tr><td>Urinary Distress Inventory (UDI-6)</td><td>Toivo et al. (2019) [37]</td></tr><tr><td>Mini Nutritional Assessment</td><td>Levine et al. (2021) [44]; Toivo et al. (2019) [37]</td></tr><tr><td>Fulmer SPICES tool</td><td>Li et al. (2021) [40]</td></tr><tr><td>Edmonton Symptom Assessment Scale (ESAS)</td><td>Possin et al. (2019) [34]</td></tr><tr><td rowspan="6">Cognitive assessment</td><td>CDC's STEADI Instrument</td><td>Goldberg et al. (2020) [39]</td></tr><tr><td>Orthostatic hypotension test</td><td>Toivo et al. (2019) [37]</td></tr><tr><td>Neuropsychiatric Inventory (NPI-Q) and Nursing Home version</td><td>Possin et al. (2019) [34]; Cateau et al. (2021) [36]; Van Der Spek et al. (2018) [46]</td></tr><tr><td>Montreal Cognitive Assessment (moca)</td><td>Levine et al. (2021) [44]; Possin et al. (2019) [34]</td></tr><tr><td>Six Item Screener</td><td>Goldberg et al. (2020) [39]</td></tr><tr><td>Blessed Orientation Memory Concentration test (BOMC)</td><td>Li et al. (2021) [40]</td></tr><tr><td rowspan="7">Functional assessment</td><td>Karnosfsky Performance Status</td><td>Li et al. (2021) [40]</td></tr><tr><td>Mini Mental State Examination (MMSE)</td><td>Toivo et al. (2019) [37]</td></tr><tr><td>Severe Impairment Battery-8</td><td>Van Der Spek et al. (2018) [46]</td></tr><tr><td>Cohen-Mansfield Agitation Inventory (CMAI)</td><td>Van Der Spek et al. (2018) [46]</td></tr><tr><td>3D Confusion Assessment Method (CAM)</td><td>Levine et al. (2021) [44]</td></tr><tr><td>Global Deterioration Scale (GDS)</td><td>Van Der Spek et al. (2018) [46]</td></tr><tr><td>Short Performance Physical Battery (SPPB)</td><td>Kari et al. (2021) [35]</td></tr><tr><td rowspan="2">Alcohol abuse detection</td><td>Functional Assessment Staging Tool (FAST)</td><td>Possin et al. (2019) [34]</td></tr><tr><td>Timed up and Go test</td><td>Levine et al. (2021) [44]; Li et al. (2021) [40]; Goldberg et al. (2020) [39]</td></tr><tr><td></td><td>Five-times-sit-to-stand test</td><td>Toivo et al. (2019) [37]</td></tr><tr><td></td><td>CAGE Substance Abuse Screening Tool</td><td>Levine et al. (2021) [44]</td></tr><tr><td></td><td>Alcohol Use Disorder Identification Test version C (AUDIT-C)</td><td>Toivo et al. (2019) [37]</td></tr></tbody></table>

could use WeChat for medication consultation, and pharmacists could reply. It was also used to follow the patients regularly to collect information on the treatment effects or adverse events. For 3 studies no information was found on the communication with the patient [32, 40, 45].

A follow-up in consultation or by phone was organized to evaluate the implementation of the decided modifications and to follow the clinical evolution of the patient. Only one study did not follow up the included patients [39]. Patients were followed up between 12 and 24 months. This follow-up was organized in person or by
phone with the nurse [44], pharmacist [47] or community health educator [34].

Table 3 classifies tools used according to assessed outcome. Thirteen articles used standardised tools to assess patients' treatment-related aspects (satisfaction, compliance, risk of DRP, severity and causality, drug interaction, appropriateness), clinical aspects (disability, physical abilities) quality of life, social skills (literacy, social appraisal) and psychological aspects (depression, anxiety, emotional burden, sleep quality, pain) [33–41, 43, 44, 46, 47]. To analyse prescriptions, the pharmacist could use different tools such as STOPP/START criteria for potentially inappropriate prescribing for older people [51], drug-drug interaction database SFINX [52], Medication Appropriateness Index [53], Systematic Tool to Reduce Inappropriate Prescribing STRIP [54] or Beers criteria [55]. To assess DRP risk, pharmacist or nurse used Drug Related Problem Risk Assessment tool [56] or Cancer and Aging Research Group chemotherapy toxicity risk score [57]. The Morisky score was the only medication adherence assessment score used in the studies [35, 38, 43]. Two studies assessed patients' satisfaction with treatment [38, 47]. Pharmacists used different DRP classifications including PCNE DRP classification V6.2 and NCC MERP Index for Categorizing Medication Errors [33, 38, 40]. To assess quality of life, some tools were filled in either by the patient himself or other professionals. We found thirteen different tools used to assess depression, anxiety, burden, or sleep disorder including Patient Health Questionnaire PHQ9 depression measure [58] and GRID Hamilton Rating Scale [59].

## Discussion

In this qualitative systematic review, 16 studies that established a multidisciplinary intervention involving a pharmacist in adult patients were identified. Multidisciplinary medication review meetings were the most common clinical pathway involving a pharmacist found in this study and could represent a gold standard intervention to prevent ADE. Medication review is a structured evaluation of a patient medicines aiming to optimize prescriptions and improving health outcomes. In this care practice, decisions are shared between professionals regarding a goal to be achieved. A systematic review proved that medication review and reconciliation with cooperation between pharmacist and general practitioner decreased significantly number of DRP, improved prescribing of medication, improved quality of life scores, improved medication appropriateness index scores, increased compliance and patient knowledge, and improved clinical values [60]. These results were also confirmed by a recently published literature review which found that multidisciplinary intervention including

pharmaceutical services (medication reconciliation and review) significantly increased patients' quality of life (OR 0,58, 95% CI 0,47–0,69) and reduced the probability of readmission by 32% [22].

Multidisciplinary medication review was generally structured in four steps: baseline assessment including clinical, pharmaceutical, biological, and psychosocial relevant data collection, preparation of a detailed analysis report by health professionals in their field of expertise, a multidisciplinary medication review meeting and a patient follow-up. There was no list of standardised medication review activities published but the different stages of the process we found were consistent with activities found in an international policy review published in 2020 that compared medication review of 6 countries [61]. In this review, comprehensive patient interview and interprofessional collaboration, found in our process, were judged clinically important.

The presence of a leader who promoted the implementation of the intervention interdisciplinary, face-to-face approaches and positive attitude by general practitioners were acknowledged as a facilitator [33]. Intervention required healthcare professionals involvement and active role, a reinforced interprofessional collaboration with information sharing [35].

Our study showed that most teams were composed of a physician/pharmacist/nurse trio (94%; 100%; 88%). This results concords with a recent systematic review that selected 29 studies from 2000 to 2018 in which multidisciplinary teams included pharmacists (n=29;100%), physicians (n=27; 93%) nurses (n=15; 52%). The composition of the team is changing, and the pharmacist/doctor duo that used to be most common now includes a nurse almost systematically. Moreover, in this systematic review other professionals were included such as psychologists (n=3; 10%) and occupational therapists (n=2; 7%). Our results showed the presence of social workers (n=3; 19%) and community health educator (n=1; 6%), physical therapists (n=4; 25%), occupational therapists (n=2; 12%). Highly specialised teams associating tripartite team to social worker and/or specialist professionals or/and physiotherapists are beginning to emerge.

Pharmacists mostly performed deprescription intervention [36] and medication review based on clinical practices guidelines to prevent and limit two of the main causes of ADE in older people: polypharmacy and inappropriate prescribing [32, 33, 36, 37, 39, 44, 46]. Indeed, elderly people (> 65 years) were targeted in more than 60% (n=10) of the interventions. Most of them lived in nursing homes (n=6). They constitute a specific population because of the frequent occurrence of polypathologies, existence of physical, psychological, or socio-economic fragility and a risk of loss of autonomy
and dependence [51–54]. However, polypathology are also common in non-elderly patient with a frequency of patients aged 40–64 reported an average of 3.4 pathologies per person [62]. In our study, interventions for non-elderly people with chronic diseases, pharmacist and team interventions were focused on the disease (chronic pain, epilepsy, diabetes) and patient did not benefit from a global assessment as seen in elderly interventions. Patients eligible for this type of intervention should be selected based on the complexity of their needs and not only on their age. Moreover, only two studies assessed medication adherence [38, 43]. Yet, medication non-adherence is a main cause of lack of optimal clinical benefit [63, 64]. It can lead to medical and psychosocial complications of the disease, reduce patients’ quality of life, waste healthcare resources [65] and potentially lead to ADE [66]. This reinforces the pharmacist’s key role in the patient’s overall assessment to prevent or limit ADE.

Involvement of the nurse in patient's care and in multidisciplinary decision-making is essential. In selected studies, their proximity to patients allowed them to speak on their behalf in multidisciplinary meetings. Nurses may be part of the patient's primary care team or may intervene during a consultation to provide care coordination, education, and in-home clinical assessment. Indeed, due to their training, nurses can detect, report, and monitor ADE emergence. In France, a recent decree specified that advanced practice nurses training should include polyparmacy identification and preparation of assessment for a multiprofessional consultation on medication reconciliation and ADE risk assessment, medication side effect identification, adherence medication monitoring, and signs of iatrogenic pathology identification throughout patient's care pathway [67].

Primary care physician's role is central. Indeed, they have a global vision of the state of health of their patients and are the pivotal person of the medication iatrogenic risk prevention in ambulatory care. Optimising medication prescribing by reassessing the benefit/risk ratio, carrying out regular clinical and biological monitoring and prioritising pathologies in consultation with the patient helps to limit risk of ADE. Physicians reluctant attitudes and weak engagement were evaluated as the main contributing factors for intervention not being implemented [37]. Building trust among healthcare professionals and between the professionals is essential for effective collaboration [35]. Six interventions of selected studies included a specialist physician but only geriatrics and psychiatrist in Levine study [44] were included in a multidisciplinary consultation meeting. Epileptologist, and emergency department clinician only performed consultation with patient and referrals to other healthcare professionals. Inclusion of specialist physicians such as

nephrologists, geriatricians, cardiologists could be considered during multidisciplinary medication reviews. Indeed, their skills are essential for making decisions that give patients the best possible care according to the state of science especially for multimorbid and complex patients.

A systematic review identified five main ADE risk factor categories: patient-related, pathology-related, drug treatment-related, care pathway-related and finally factors related to the patient's genetics [68]. Other risk factors (e.g. polypharmacy, polypathology) were identified such as psychosocial factors or complexity of patient's care path. Thus, it is legitimate to include in the team other health professionals (social worker, psychologist, physical therapist) who are better able to assess the patient and propose appropriate solutions when an at-risk situation is detected. Three studies included social worker in the multidisciplinary team. A combined pharmacist and a social worker-led program to address psychosocial factors demonstrated a significant reduction in 30-day, all-cause readmission rates to the same hospital [69]. The inclusion of social workers in the patient's care pathway allows detecting depression, anxiety, or social withdrawal. Moreover, psychosocial support may also decipher medication non-adherence meaning, detect suffering, levers, obstacles to medication adherence, and assess patient's resources attitudes, perception, and beliefs assessment.

To appraise study quality, we selected randomized controlled trials and we used TIDieR checklist [29]. This checklist was developed to improve the completeness of reporting, and the replicability of interventions. It allowed us to highlight the lack of description of the implementation evaluation (acceptability, appropriateness, feasibility, fidelity) in selected studies. Only three studies published a process, an implementation evaluation or a qualitative study about their intervention [49, 50, 70], this studies have generally reported good results. However, some limitations have been highlighted. Concerns about feasibility, mainly due to time and resource constraints [33, 35–37, 40, 44, 47] were raised. For example, pharmacist did not participate in home-based care team in Levine's study owing to limited time and resources, which represented a potential weakness [44]. To limit time constraint, GAIN intervention developers will assess the feasibility of implementing geriatric assessment driven interventions via telehealth in community practice [40]. In the GAPCare intervention board-certified resident pharmacists were trained to supplement pharmacist's activities [39]. In Kari et al. study, it seemed important to better target patients who were most likely to benefit from these time-consuming interventions [35]. It would be beneficial to encourage health professionals working in multidisciplinary teams to publish their implementation studies to inform
health intervention research, enable replication of the inter-
vention and increase the potential impact of research on
health.

Our descriptive analysis did not lead us to perform
quantitative analysis however it would be interesting to
extend the research question with a quantitative analysis
with meta-analysis to evaluate the impact of multidisci-
plinary management to a conventional management.

Limitations

This qualitative systematic review only included rand-
omized controlled trials for quality reasons. Therefore, we
did not review multidisciplinary interventions assessed
with other methods. The inclusion of grey literature could
have had a real benefit for our research question but it also
requires a huge amount of time and resource to search.
We have chosen to select only 3 reliable sources and not to
include the grey literature, however it would be interest-
ing to take the time to compare the results we were able to
obtain with the results that the grey literature would have
given us. We did not perform a quantitative analysis due
to heterogeneity in outcome, intervention methods, par-
ticipants' demographics and settings of the included stud-
ies. However, we attempted to examine included studies
using the standardised TIDieR checklist. Another poten-
tial limitation is the language selection; we only included
articles published in English. It would be interesting to
extend the search to articles written in other languages.
Quality of this synthesis also depended on available data
in intervention description; some information was not
found and may limit our findings.

Conclusions

This article is the first systematic review selecting ran-
domised clinical trial and their implementation studies
to analyse the process of multidisciplinary care includ-
ing a pharmacist. In the context of growing complex care,
multidisciplinary medication review meetings appear
to be the common structure to ensure the effectiveness
and safety of care. Essential to the diagnosis and man-
agement of patients, these meetings gather all the health
professionals essential during four stages (data collection,
appraisal report, multidisciplinary meeting, and follow-
up) to establish a coordinated care plan. The compre-
hensive assessment of complex chronic patients by the
tripartite team of physician, pharmacist and nurse should
be completed with other professionals' skills to consider
all the ADE risk factors described in the literature.

Abbreviations

<table>
   <tr>
    <td>
     ADE
    </td>
    <td>
     Adverse Drug Event
    </td>
   </tr>
   <tr>
    <td>
     ADR
    </td>
    <td>
     Adverse Drug Reactions
    </td>
   </tr>
   <tr>
    <td>
     DRP
    </td>
    <td>
     Drug-Related Problems
    </td>
   </tr>
   <tr>
    <td>
     ENEIS
    </td>
    <td>
     Enquête Nationale sur les Événements Indésirables liés aux Soins (French national survey on adverse events in healthcare)
    </td>
   </tr>
   <tr>
    <td>
     ME
    </td>
    <td>
     Medication errors
    </td>
   </tr>
   <tr>
    <td>
     NCC MERP Index for Categorizing Medication Errors
    </td>
    <td>
     National coordination council for medication error reporting and prevention Index for Categorizing Medication Errors
    </td>
   </tr>
   <tr>
    <td>
     PCNE DRP classification
    </td>
    <td>
     Pharmaceutical Care Network Europe Drug Related Problem classification
    </td>
   </tr>
   <tr>
    <td>
     PHQ9
    </td>
    <td>
     Patient Health Questionnaire 9
    </td>
   </tr>
   <tr>
    <td>
     PRISMA
    </td>
    <td>
     Preferred Reporting Items for Systematic Reviews and Meta-Analyses
    </td>
   </tr>
   <tr>
    <td>
     QALY
    </td>
    <td>
     Quality-adjusted life year
    </td>
   </tr>
   <tr>
    <td>
     REDcap
    </td>
    <td>
     Research Electronic Data Capture
    </td>
   </tr>
   <tr>
    <td>
     STOPP/START
    </td>
    <td>
     Screening Tool of Older People's Prescriptions/ Screening Tool to Alert to Right Treatment
    </td>
   </tr>
   <tr>
    <td>
     STRIP
    </td>
    <td>
     Systematic Tool to Reduce Inappropriate Prescribing
    </td>
   </tr>
   <tr>
    <td>
     TIDieR
    </td>
    <td>
     Template for Intervention Description and Replication
    </td>
   </tr>
  </table>

**Supplementary Information**

The online version contains supplementary material available at https://doi.
org/10.1186/s12913-023-09512-6.

Additional file 1.

Acknowledgements

Not applicable

Authors' contributions

S.Z. and H.R. wrote the main manuscript. S.Z. prepared Figs. 1 and 2 and Tables 1, 2, 3. All authors reviewed the manuscript. The author(s) read and approved the final manuscript.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Availability of data and materials

All data generated or analysed during this study are included in this published
article.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Pharmacy, Nimes University Hospital, University of Montpellier, Nimes, France. ²Desbrest Institute of Epidemiology and Public Health, Univ Montpellier, INSERM, Montpellier, France. ³Department of Law and Health Economics, Faculty of Pharmacy, University of Montpellier, Montpellier, France.
Received: 18 October 2022 Accepted: 7 May 2023

Published online: 30 August 2023

## References

1. Garin N, Sole N, Lucas B, Matas L, Moras D, Rodrigo-Troyano A, Gras-Martin L, Fonts N. Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions. Sci Rep. 2021;11(1):883. https://doi.org/10.1038/s41598-020-80560-2.

2. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274(1):29-34.

3. Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, Gallivan T, Hallisey R, Ives J, Laird N, Laffel G, et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA. 1995;274(1):35-43.

4. Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38(5):437-53. https://doi.org/10.1007/s40264-015-0281-0.

5. Michel P, Minodier C, Lathelize M, Motty-Monnereau C, Dmecq S, Chaileix M. Les évènements indésirables graves associés aux soins observés dans les établissements de santé. Dossiers Solidarité et santé n 17. Paris; 2010:8. https://drees.solidarites-sante.gouv.fr/sites/default/files/2020-10/dss17.pdf.

6. Michel P, Quenon JL, Djihoud A, Tricaud-Vialle S, Sarasqueta AM, Dmecq S. Les évènements indésirables graves liés aux soins observés dans les établissements de santé : premiers résultats d'une étude nationale. Etudes et résultats. 2005;2005:16. https://drees.solidarites-sante.gouv.fr/sites/default/files/2020-10/er398-3.pdf.

7. Hanlon JT, Schmader KE, Koronkowski MJ, Weinberger M, Landsman PB, Samsa GP, Lewis IK. Adverse drug events in high risk older outpatients. J Am Geriatr Soc. 1997;45(8):945-8. https://doi.org/10.1111/j.1532-5415.1997.tb02964.x.

8. Onder G, Pedone C, Landi F, Cesari M, Della Vedova C, Bernabei R, Gambassi G. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc. 2002;50(12):1962-8. https://doi.org/10.1046/j.1532-5415.2002.50607.x.

9. Field TS, Gurwitz JH, Harrold LR, Rothschild J, DeBellis KR, Seger AC, Auger JC, Garber LA, Cadoret C, Fish LS, Garber LD, Kelleher M, Bates DW. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc. 2004;52(8):1349-54. https://doi.org/10.1111/j.1532-5415.2004.52367.x.

10. Mugosa S, Bukumirić Z, Kovacević A, Bosković A, Protić D, Todorović Z. Adverse drug reactions in hospitalized cardiac patients: characteristics and risk factors. Vojnosanit Pregl. 2015;72(11):975-81. https://doi.org/10.2298/vsp140710104m.

11. Evans RS, Lloyd JF, Stoddard GJ, Nebeker JR, Samore MH. Risk factors for adverse drug events: a 10-year analysis. Ann Pharmacother. 2005;39(7-8):1161-8. https://doi.org/10.1345/aph.1E642.

12. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Far-rar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-9. https://doi.org/10.1136/bmj.329.7456.15.

13. Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging. 2014;9:2079-86. https://doi.org/10.2147/CIA.S71178.

14. Institute of Medicine (US) Committee on Quality of Health Care in America. To Err is Human: Building a Safer Health System. Kohn LT, Corrigan JM, Donaldson MS, editors. Washington (DC): National Academies Press (US); 2000. PMID: 25077248.

15. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166(9):955-64. https://doi.org/10.1001/archinte.166.9.955.

16. Knudsen P, Herborg H, Mortensen AR, Knudsen M, Hellebek A. Preventing medication errors in community pharmacy: frequency and seriousness of medication errors. Qual Saf Health Care. 2007;16(4):291-6. https://doi.org/10.1136/qshc.2006.018770.

17. Guignard B, Bonnabry P, Perrier A, Dayer P, Desmeules J, Samer CF. Drug-related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologist. Eur J Intern Med. 2015;26(6):399-406. https://doi.org/10.1016/j.ejim.2015.05.012.

18. Schnipper JL, Kirwin JL, Cotugno MC, Wahlstrom SA, Brown BA, Tarvin E, Kachalia A, Horng M, Roy CL, McKean SC, Bates DW. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med. 2006;166(5):565-71. https://doi.org/10.1001/archinte.166.5.565.

19. Blouin RA, Adams ML. The Role of the Pharmacist in Health Care: Expanding and Evolving. N C Med J. 2017;78(3):165-7. https://doi.org/10.18043/ncm.78.3.165.

20. Bouchaud L, Bluze E, Dussart C, Massoubre B, Bouliat C. Le rôle du pharmacien en officine et en pharmacie hospitalière dans la prévention en santé publique en France [The role of the community and hospital pharmacist in public health prevention in France]. Ann Pharm Fr. 2022;80(6):769-77. French. https://doi.org/10.1016/j.pharma.2022.02.004.

21. World Health Organization. Global patient safety action plan 2021-2030: towards eliminating avoidable harm in health care. Geneva: World Health Organization; 2021. Disponible sur. [Cité 9 mai 2022]. https://apps.who.int/iris/handle/10665/343477.

22. Ruiz-Ramos J, Hernández MH, Juanes-Borrego AM, Milà R, Mangues-Bafal-luy MA, Mestres C. The Impact of Pharmaceutical Care in Multidisciplinary Teams on Health Outcomes: Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2021;22(12):2518-26. https://doi.org/10.1016/j.jamda.2021.05.038.

23. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140(10):795-801. https://doi.org/10.7326/0003-4819-140-10-200405180-0009.

24. Working groups items - Pharmaceutical Care Network Europe. Disponible sur. [Cité 12avr 2022]. https://www.pcne.org/working-groups/2/drug-related-problem-classification.

25. D'Amour D, Ferrada-Videla M, San Martin Rodriguez L, Beaulieu MD. The conceptual basis for interprofessional collaboration: core concepts and theoretical frameworks. J Interprof Care. 2005;19 Suppl 1:116-31. https://doi.org/10.1080/13561820500082529.

26. McKay CA, Crippen L. Collaboration through clinical integration. Nurs Adm Q. 2008;32(2):109-16. https://doi.org/10.1097/01.NAQ.0000314539.44488.e6.

27. Baggs JG, Schmitt MH. Collaboration between nurses and physicians. Image J Nurs Sch. 1988;20(3):145-9. https://doi.org/10.1111/j.1547-5069.1988.tb00055.x.

28. National Institute for Health Research. International prospective register of systematic reviews (PROSPERO). https://www.crd.york.ac.uk/prospero/.

29. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, Altman DG, Barbour V, Macdonald H, Johnston M, Lamb SE, Dixon-Woods M, McCulloch P, Wyatt JC, Chan AW, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. https://doi.org/10.1136/bmj.g1687.

30. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN. REDCap Consortium. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208. https://doi.org/10.1016/j.jbi.2019.103208.

31. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-81. https://doi.org/10.1016/j.jbi.2008.08.010.

32. Desborough JA, Clark A, Houghton J, Sach T, Shaw V, Kirthingha V, Holland RC, Wright DJ. Clinical and cost effectiveness of a multi-professional medication reviews in care homes (CAREMED). Int J Pharm Pract. 2020;28(6):626-34. https://doi.org/10.1111/ijpp.12656.

33. Strauven G, Anrys P, Vandael E, Henrard S, De Lepeleire J, Spinewine A, Foulon V. Cluster-Controlled Trial of an Intervention to Improve Prescribing in Nursing Homes Study. J Am Med Dir Assoc. 2019;20(11):1404-11. https://doi.org/10.1016/j.jamda.2019.06.006.

34. Possin KL, Merrilees JJ, Dulaney S, Bonasera SJ, Chiong W, Lee K, Hooper SM, Allen IE, Braley T, Bernstein A, Rosa TD, Harrison K, Begert-Hellings H, Kornak J, Kahn JG, Naasan G, Lanata S, Clark AM, Chodos A, Gearhart R,
Ritchie C, Miller BL. Effect of Collaborative Dementia Care via Telephone and Internet on Quality of Life, Caregiver Well-being, and Health Care Use: The Care Ecosystem Randomized Clinical Trial. JAMA Intern Med. 2019;179(12):1658–67. https://doi.org/10.1001/jamainternmed.2019.4101.

35. Kari H, Jiijö-Jensen N, Kortejärvi H, Ronkainen J, Yliptuttla M, Laaksonen R, Blom M. Effectiveness and cost-effectiveness of a people-centred care model for community-living older people versus usual care — A randomised controlled trial. Res Social Adm Pharm. 2022;18(6):3004–12. https://doi.org/10.1016/j.sapharm.2021.07.025.

36. Cateau D, Ballabeni P, Niquille A. Effects of an interprofessional depre-
scribing intervention in Swiss nursing homes: the Individual Depre-
scribing Intervention (IDel) randomised controlled trial. BMC Geriatr.
2021;21(1):655. https://doi.org/10.1186/s12877-021-02465-7.

37. Toivo T, Airaksinen M, Dimitrow M, Savela E, Pelkonen K, Kiuru V, Suominen T, Uunimäki M, Kivelä SL, Leikola S, Puustinen J. Enhanced coordination of care to reduce medication risks in older home care clients in primary care: a randomized controlled trial. BMC Geriatr. 2019;19(1):332. https://doi.org/10.1186/s12877-019-1353-2.

38. Roustit M, Chaumais MC, Chapuis C, Gairard-Dory A, Hadjard C, Chanoine S, Allenet B, Sitbon O, Pison C, Bedouch P. ETHAP Study Group. Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial. Int J Clin Pharm. 2020;42(4):1128–38. https://doi.org/10.1007/s11096-020-01047-8.

39. Goldberg EM, Marks SJ, Ilegbusi A, Resnik L, Strauss DH, Merchant RC. GAPCare: The Geriatric Acute and Post-Acute Fall Prevention Intervention in the Emergency Department: Preliminary Data. J Am Geriatr Soc. 2020;68(1):198–206. https://doi.org/10.1111/jgs.16210.

40. Li D, Sun CL, Kim H, Soto-Perez-de-Celis E, Chung V, Koczywas M, Fakih M, Chao J, Cabrera Chien L, Charles K, Hughes SFDS, Kathera V, Trent M, Roberts E, Jayani R, Moreno J, Kelly C, Sedrak MS, Dale W. Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021;7(11):e214158. https://doi.org/10.1001/jamaoncol.2021.4158.

41. DeBar L, Benes L, Bonifay A, Deyo RA, Elder CR, Keefe FJ, Leo MC, McMullen C, Mayhew M, Owen-Smith A, Smith DH, Trinacty CM, Vollmer WM. Interdisciplinary team-based care for patients with chronic pain on long-term opioid treatment in primary care (PPACT) - Protocol for a pragmatic cluster randomized trial. Contemp Clin Trials. 2018;67:91–9. https://doi.org/10.1016/j.cct.2018.02.015.

42. Lu Z, Li Y, He Y, Zhai Y, Wu J, Wang J, Zhao Z. Internet-Based Medication Management Services Improve Glycated Hemoglobin Levels in Patients with Type 2 Diabetes. Telemed J E Health. 2021;27(6):686–93. https://doi.org/10.1089/tmj.2020.0123.

43. Zheng Y, Ding X, Guo Y, Chen Q, Wang W, Zheng Y, Wang S, Ding Y, Ding M. Multidisciplinary management improves anxiety, depression, medication adherence, and quality of life among patients with epilepsy in eastern China: A prospective study. Epilepsy Behav. 2019;100(Pt A):106400. https://doi.org/10.1016/j.ebehav.2019.07.001.

44. Levine AMP, Emonds EE, Smith MA, Rickles NM, Kuchel GA, Steffens DC, Ohlheiser A, Fortinsky RH. Pharmacist Identification of Medication Therapy Problems Involving Cognition Among Older Adults Followed by a Home-Based Care Team. Drugs Aging. 2021;38(2):157–68. https://doi.org/10.1007/s40266-020-00821-7.

45. Connolly MJ, Broad JB, Bish T, Zhang X, Bramley D, Kerse N, Bloomfield K, Boyd M. Reducing emergency presentations from long-term care: A before-and-after study of a multidisciplinary team intervention. Maturitas. 2018;117:45–50. https://doi.org/10.1016/j.maturitas.2018.08.014.

46. van der Spek K, Koopmans RTCM, Smalbrugge M, Nelissen-Vrancken MHJMG, Wetzels RB, Smeets CHW, de Vries E, Teerenstra S, Zuidema SU, Gerritsen DL. The effect of biannual medication reviews on the appropriateness of psychotropic drug use for neuropsychiatric symptoms in patients with dementia: a randomised controlled trial. Age Ageing. 2018;47(3):430–7. https://doi.org/10.1093/ageing/afy001.

47. Siaw MYL, Ko Y, Malone DC, Tsou KYK, Lew YJ, Foo D, Tan E, Chan SC, Chia A, Sinaram SS, Goh KC, Lee JY. Impact of pharmacist-involved collaborative care on the clinical, humanistic and cost outcomes of high-risk patients with type 2 diabetes (IMPACT): a randomized controlled trial. J Clin Pharm Ther. 2017;42(4):475–82. https://doi.org/10.1111/jcpt.12536.

48. DeBar L. Primary Care-Based Behavioral Treatment for Long-Term Opioid Users with Chronic Pain: Primary Results and Lessons Learned from the

PPACT Pragmatic Trial. 35. https://dcricollab.dcri.duke.edu/sites/NIHKR/KR/GR-Slides-12-03-21.pdf.

49. Anrys P, Strauven G, Roussel S, Vande Ginste M, De Lepeleire J, Foulon V, Spinewine A. Process evaluation of a complex intervention to optimize quality of prescribing in nursing homes (COME-ON study). Implement Sci. 2019;14(1):104. https://doi.org/10.1186/s13012-019-0945-8.

50. Foley RA, Hurard LL, Cateau D, Koutaissoff D, Bugnon O, Niquille A. Physicians' Nurses' and Pharmacists' Perceptions of Determinants to Deprescribing in Nursing Homes Considering Three Levels of Action: A Qualitative Study. Pharmacy (Basel). 2020;8(1):17. https://doi.org/10.3390/pharmacy8010017.

51. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8. https://doi.org/10.1093/ageing/afu145. Epub 2014 Oct 16. Erratum in: Age Ageing. 2018;47(3):489.

52. Böttiger Y, Laine K, Andersson ML, Korhonen T, Molin B, Ovesjö ML, Tirkkonen T, Rane A, Gustafsson LL, Eiermann B. SFINX-a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol. 2009;65(6):627–33. https://doi.org/10.1007/s00228-008-0612-5.

53. Spinewine A, Dumont C, Mallet L, Swine C. Medication appropriateness index: reliability and recommendations for future use. J Am Geriatr Soc. 2006;54(4):720–2. https://doi.org/10.1111/j.1532-5415.2006.00668_8.x.

54. Drenth-van Maanen AC, Leendertse AJ, Jansen PAF, Knol W, Keijsers CJPW, Meulendijk MC, van Marum RJ. The Systematic Tool to Reduce Inappropriate Prescribing (STRIP): Combining implicit and explicit prescribing tools to improve appropriate prescribing. J Eval Clin Pract. 2018;24(2):317–22. https://doi.org/10.1111/jep.12787.

55. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674–94. https://doi.org/10.1111/jgs.15767.

56. Dimitrow MS, Mykkänen SI, Leikola SN, Kivelä SL, Lyles A, Airaksinen MS. Content validation of a tool for assessing risks for drug-related problems to be used by practical nurses caring for home-dwelling clients aged ≥65 years: a Delphi survey. Eur J Clin Pharmacol. 2014;70(8):991–1002. https://doi.org/10.1007/s00228-014-1699-5.

57. Ostwal V, Ramaswamy A, Bhargava P, Hatkhambkar T, Swami R, Rastogi S, Mandavkar S, Ghosh J, Bajpai J, Gulia S, Srinivas S, Rath S, Gupta S. Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study. BMJ Open. 2021;11(6):e047376. https://doi.org/10.1136/bmjopen-2020-047376.

58. Löwe B, Kroenke K, Herzog W, Gräfe K. Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). J Affect Disord. 2004;81(1):61–6. https://doi.org/10.1016/S0165-0327(03)00198-8.

59. Williams JB, Kobak KA, Bech P, Engelhardt N, Evans K, Lipsitz J, Olin J, Pearson J, Kalali A. The GRID-HAMD: standardization of the Hamilton Depression Rating Scale. Int Clin Psychopharmacol. 2008;23(3):120–9. https://doi.org/10.1097/YIC.0b013e3282f948f5.

60. Geurts MM, Talsma J, Brouwers JR, de Gier JJ. Medication review and reconciliation with cooperation between pharmacist and general practitioner and the benefit for the patient: a systematic review. Br J Clin Pharmacol. 2012;74(1):16–33. https://doi.org/10.1111/j.1365-2125.2012.04178.x.

61. Rose O, Cheong VL, Dhaliwall S, Eislage K, Erzkamp S, Jorgenson D, Martínez F, Luetsch K. Standards in medication review: An international perspective. Can Pharm J (Ott). 2020;153(4):215–23. https://doi.org/10.1177/1715163520929665.

62. Allonier C, Dourgnon P. Enquête sur la santé et la protection sociale 2008:258. https://www.irdes.fr/Publications/Rapports2010/rap1800.pdf.

63. Dunbar-Jacob J, Erlen JA, Schlenk EA, Ryan CM, Sereika SM, Doswell WM. Adherence in chronic disease. Annu Rev Nurs Res. 2000;18:48–90. PMID: 10918932.

64. Rybacki JJ. Improving cardiovascular health in postmenopausal women by addressing medication adherence issues. J Am Pharm Assoc (Wash). 2002;42(1):63–71; quiz 72-3. https://doi.org/10.1331/108658002763538099.
65. World Health Organization. Adherence to long-term therapies: evidence for action. World Health Organization; 2003. https://apps.who.int/iris/handle/10665/42682.

66. Leporini C, De Sarro G, Russo E. Adherence to therapy and adverse drug reactions: is there a link? Expert Opin Drug Saf. 2014;13 Suppl 1:S41–55. https://doi.org/10.1517/14740338.2014.947260.

67. Arrêté du 12 août 2019 modifiant l'arrêté du 18 juillet 2018 relatif au régime des études en vue du diplôme d'Etat d'infirmier en pratique avancée - Légifrance.pdf. https://www.legifrance.gouv.fr/loda/id/JORFT EXT000038914201/.

68. Zhou L, Rupa AP. Categorization and association analysis of risk factors for adverse drug events. Eur J Clin Pharmacol. 2018;74(4):389–404. https://doi.org/10.1007/s00228-017-2373-5.

69. Gil M, Mikaitis DK, Shier G, Johnson TJ, Sims S. Impact of a combined pharmacist and social worker program to reduce hospital readmissions. J Manag Care Pharm. 2013;19(7):558–63. https://doi.org/10.18553/jmcp.2013.19.7.558.

70. Dorflinger LM, Ruser C, Sellinger J, Edens EL, Kerns RD, Becker WC. Integrating interdisciplinary pain management into primary care: development and implementation of a novel clinical program. Pain Med. 2014;15(12):2046–54. https://doi.org/10.1111/pme.12554.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

* fast, convenient online submission

* thorough peer review by experienced researchers in your field

* rapid publication on acceptance

* support for research data, including large and complex data types

* gold Open Access which fosters wider collaboration and increased citations

* maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

<figure><img src="image_5.png" /></figure>

BMC